Jeffrey A. Boyd, MBA1*, Bruce L. Levine, PhD2,3, Kathrin Jinivizian, BS1*, Margit A. Jeschke, PhD1*, Megan M. Suhoski Davis, PhD3,4*, Zhaohui Zheng, MS3,5*, Daniel Stark, PhD6*, Liza Loidolt, MS, MBA1*, Christopher H. Keir, MD, MS7 and Patricia A. Wood, MD, PhD7
1Cell & Gene Therapies Unit, Novartis Pharmaceuticals Corporation, Morris Plains, NJ
2Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
3Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
4Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
5Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
6Cell & Gene Therapies Unit, Novartis Pharma AG, Basel, Switzerland
7Cell & Gene Therapies Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ